MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

doi:10.1002/1878-0261.13397

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

Molecular oncology - 1 Nov 2023

Fernandes Marie, Hoggard Brynna, Jamme Philippe, Paget Sonia, Truong Marie-José, Grégoire Valérie, Vinchent Audrey, Descarpentries Clotilde, Morabito Angela, Stanislovas Justas, Farage Enoir, Meneboo Jean-Pascal, Sebda Shéhérazade, Bouchekioua-Bouzaghou Katia, Nollet Marie, Humez Sarah, Perera Timothy, Fromme Paul, Grumolato Luca, Figeac Martin, Copin Marie-Christine, Tulasne David, Cortot Alexis B, Kermorgant Stéphanie, Kherrouche Zoulika

Abstract excerpt

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3-4% of non-small-cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET-tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exons

Share to Hepatocyte Growth Factor

Share to Lung Neoplasms

Share to Mice

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 36799689
DOI: 10.1002/1878-0261.13397
PMCID: PMC10620121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.PMID 36799689Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.Semantic proximity Read ↗

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.Semantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.Semantic proximity Read ↗

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerSemantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.Semantic proximity Read ↗

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Semantic proximity Read ↗

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.